Precigen (PGEN) Common Equity (2012 - 2026)

Precigen (PGEN) has 15 years of Common Equity data on file, last reported at $20.2 million in Q1 2026.

• On a quarterly basis, Common Equity rose 243.92% year-over-year to $20.2 million in Q1 2026; TTM through Mar 2026 was $20.2 million, a 243.92% increase from a year earlier, with the FY2024 full-year figure at $38.5 million, down 67.5% from the prior year.
• Common Equity for Q1 2026 stood at $20.2 million, down from $41.9 million in the prior quarter.
• Over the last five years, Common Equity for PGEN reached as high as $184.1 million in Q1 2023 and fell as low as -$36.8 million in Q2 2025.
• Historically, Common Equity has averaged $78.8 million across 5 years, with a median of $64.7 million in 2022.
• Across the five-year window, Common Equity slumped 185.2% in 2025 and jumped 243.92% in 2026, its largest moves.
• Year by year, Common Equity stood at $126.3 million in 2022, then retreated by 6.15% to $118.5 million in 2023, then plunged by 67.5% to $38.5 million in 2024, then advanced by 8.71% to $41.9 million in 2025, then plunged by 51.67% to $20.2 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $20.2 million in Q1 2026, $41.9 million in Q3 2025, and -$36.8 million in Q2 2025.